Live Online Training: Ph. Eur., USP and other Pharmacopoeias - Dealing with different compendial methods

Live Online Training: Ph. Eur., USP and other Pharmacopoeias - Dealing with different compendial methods

Course No 18308

Note: All times mentioned are CEST.


There is unfortunately no recording available for this Online Training Course. However, are you interested in participating in an upcoming Live Online date of this Training Course? Or do you need any assistance on our Training Courses & Conference programme? Then simply use the following contact form to send us your request.

If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail:


Dr Raphael Bar, BR Consulting, formerly with Teva, Israel
Dr Bernd Renger, Member of the Analytical QC Working Group of the ECA Foundation
Dr Ulrich Rose, EDQM, France


It is important to understand the structure and the procedures of the different Pharmacopoeias. Some general chapters and the monographs of some widely used excipients have already been harmonised between the most important Pharmacopoeias, USP, Ph. Eur. and JP in the context of the Pharmacopoeial Discussion Group (PDG). But for a large number of general methods  differences still exist. Therefore some of the frequently asked questions are:
  • How to use alternative procedures and interchangeable methods?
  • What are the allowed exceptions to the obligation to perform all tests?
  • How can multi-compendial testing strategies look like?
  • How to prove equivalence?
In addition, PDG harmonisation does not include upcoming important pharmacopoeias like Indian and Chinese Pharmacopoeias.

This Education Course will discuss these issues and provides support in order to successfully deal with compendial methods and their differences.


Pharmaceutical companies have to follow Pharmacopoeia standards in order to meet regulatory requirements. However, there is no single Pharmacopoeia which can be applied in all regions. The US FDA may enforce USP monographs which then become mandatory whereas compliance with Ph. Eur. is mandatory in 38 countries and the EU and is applied in over 100 countries worldwide. Moreover, also other Pharmacopoeias exist in the world like the Japanese (included in the PDG harmonisation process) , Chinese, Russian or Indian Pharmacopoeias.

But what are the differences and how to deal with quality standards and test methods if products are manufactured and released for different markets?

Target Group

This Education Course addresses employees and managers from Quality Control Labs. It also addresses colleagues working in Quality Assurance and Regulatory Affairs department.

Technical Requirements

For our webinars, we use Cisco WebEx, one of the leading suppliers of online meetings. At you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.


Programme Day 1
09.00 – 09.15 h Welcome and Introduction
Session 1: Introduction to Pharmacopoeial Testing
09.15 – 10.15 h
Structure, General Methods and challenges of Ph. Eur.
10.15 – 11.00 h
Structure, monographs and activities of USP
  • Structure of Ph. Eur. and  USP
  • Meeting Pharmacopoeial standards and Pharmacopoeial Designation
  • The USP approach: Single Testing
  • Structure of  USP monographs:
    • modern monograph
    • flexible monograph
  • Structure of European Pharmacopoeia
  • Structure of  Ph. Eur.  monographs
  • What the Pharmacopoeia does not say about a procedure
  • Dietary Supplements, API and CEP of Ph. Eur.
  • Mechanisms of harmonisation between Pharmacopoeias
11.00 – 11.15 h Coffee break
11.15 – 12.15 h
Additional Pharmacopoeias around the world – Japan, China, India, Int. Ph. (WHO), BP
  • Historical developments
  • The development of the International Pharmacopoeia
  • JP, ChP, Russian Ph., and IP – similarities and differences
  • Legal status and enforcement
  • WHO Good pharmacopoeial Practices
12.15 – 12.45 h Q&A Session 1
12.45 – 13.45 h Lunch break
Session 2: Important Monographs: Harmonisation, Differences, Solutions
13.45 – 14.45 h
Pharmacopoeial policy of impurities testing
  • Which impurities are controlled?
  • Analytical techniques and general texts/monographs
  • Control of organic impurities
  • What about validation?
14.45 – 15.30 h
Analytical Instrument Qualification according to Ph. Eur. and USP
  • USP General Chapter <1058> Analytical Instrument Qualification and Ph. Eur.
  • Type of instruments and risk assessment
  • Qualification steps: DQ, IQ, OQ and PQ
  • Roles and responsibilities
  • Computerized data systems in laboratory
  • Examples: Qualification of HPLC and analytical balances
15.30 – 15.45 h Coffee Break
15.45 – 16.30 h
Life cycle approach to compendial methods
  • Draft USP chapter <1220> & Measurement Uncertainty
  • USP Chapters <1224>, <1225>, <1226>
  • Analytical Target Profile and Analytical Control Strategy
  • ICH Q2(R2) Revision
  • ICH Q14 Analytical Procedure Development
16.30 – 17.00 h Q&A Session 2
Programme Day 2
Session 3: Dealing with testing challenges
08.30 – 09.15 h
General Notices – Definitions and Requirements
  • Use of alternative procedures & interchangeable methods
  • Waivers to the obligation to perform all tests
  • Scope of general monographs
  • Definitions
09.15 – 10.15 h
Reference Standards - similarities and differences
  • Definitions and guidelines
  • Legal status of reference standards
  • Types of standards
  • Establishment and use/Testing and value assignment
  • Similarities and differences between pharmacopoeias
10.15 – 10.30 h   Coffee Break
10.30 – 11.30 h
Verification of Compendial Procedures
  • Difference between Verification and Transfer of an analytical procedure
  • Chemical vs microbiological procedures
  • Minimal performance characteristics to be verified
  • What to verify in procedures for high-level (Assay by HPLC) and low-level analytes (Impurities by HPLC and TLC)
  • When procedure verification is not required
  • ISO 17025 requirements for method verification
  • Documentation of procedure verification
11.30 – 12.00 h Q&A Session 3
12.00 – 13.00 h Lunch Break
13.00 – 14.00 h
Multicompendial Testing Strategies
  • Divergent and conflicting pharmacopoeial requirements
  • CDER’s MAPP 5310.7 “Acceptability of Standards from Alternative Compendia”
  • How to proceed in case of missing harmonization?
  • Full Testing, Worst Case Testing, Alternative Testing
  • How to proof equivalence?
14.00 – 14.45 h
Case Studies: Meeting Challenges of Pharmacopoeial Compliance
14.45 – 15.00 h Coffee Break
15.00 – 16.00 h
Alternative methods to pharmacopoeial methods: Equivalence testing of two methods
  • Is a compendial procedure equivalent to an in-house validated procedure?
  • Critical performance characteristics to be compared
  • Plotting the results of comparative testing
  • Traditional way of comparison of two procedures
  • Equivalence testing with two one-sided  t-test (TOST)
16.00 – 16.30 h Q&A Session 4 / End of the course

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information